Gorantla S, Prince G, Osius J, Dinesh D, Boddu V, Duyster J
Front Oncol. 2024; 14:1430833.
PMID: 39091915
PMC: 11291247.
DOI: 10.3389/fonc.2024.1430833.
Gorantla S, Mueller T, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J
Mol Oncol. 2023; 18(2):415-430.
PMID: 38104968
PMC: 10850816.
DOI: 10.1002/1878-0261.13566.
Moradabadi A, Farsinejad A, Khansarinejad B, Fatemi A
Exp Hematol Oncol. 2019; 8:10.
PMID: 31165012
PMC: 6489328.
DOI: 10.1186/s40164-019-0134-0.
Langabeer S, Conneally E, Flynn C
Case Rep Hematol. 2018; 2018:4378310.
PMID: 29682367
PMC: 5842720.
DOI: 10.1155/2018/4378310.
Langabeer S
JAKSTAT. 2017; 5(2-4):e1248011.
PMID: 28144498
PMC: 5215010.
DOI: 10.1080/21623996.2016.1248011.
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter P, Sarosiek K, Lin K, Meggendorfer M, Schnittger S, Letai A
Sci Signal. 2014; 7(357):ra122.
PMID: 25538080
PMC: 4353591.
DOI: 10.1126/scisignal.2005301.
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.
Krauth M, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M
Leukemia. 2014; 29(3):660-7.
PMID: 25110071
DOI: 10.1038/leu.2014.243.
The molecular regulation of Janus kinase (JAK) activation.
Babon J, Lucet I, Murphy J, Nicola N, Varghese L
Biochem J. 2014; 462(1):1-13.
PMID: 25057888
PMC: 4112375.
DOI: 10.1042/BJ20140712.
A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.
Wu Z, Zhang Y, Zhang X, Xu X, Kang Z, Li S
Biomed Res Int. 2014; 2014:458457.
PMID: 24729973
PMC: 3960525.
DOI: 10.1155/2014/458457.
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W
Leukemia. 2014; 28(7):1449-58.
PMID: 24402164
DOI: 10.1038/leu.2014.4.
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese L, Ungureanu D, Liau N, Young S, Laktyushin A, Hammaren H
Biochem J. 2013; 458(2):395-405.
PMID: 24354892
PMC: 4085142.
DOI: 10.1042/BJ20131516.
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C
Haematologica. 2012; 98(2):e15-7.
PMID: 22929973
PMC: 3561444.
DOI: 10.3324/haematol.2012.072538.
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V
Blood. 2012; 120(15):3080-8.
PMID: 22919025
PMC: 3580040.
DOI: 10.1182/blood-2012-01-404863.
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F
Haematologica. 2012; 97(12):1890-4.
PMID: 22733026
PMC: 3685285.
DOI: 10.3324/haematol.2012.065375.
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V
Haematologica. 2012; 97(10):1582-5.
PMID: 22511494
PMC: 3487560.
DOI: 10.3324/haematol.2012.064683.
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
Majumder A, Magis A, Park S, Figueroa N, Baskin R, Kirabo A
Exp Hematol. 2011; 40(1):22-34.
PMID: 22019628
PMC: 3237899.
DOI: 10.1016/j.exphem.2011.10.003.
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.
Gnanasambandan K, Sayeski P
Curr Med Chem. 2011; 18(30):4659-73.
PMID: 21864276
PMC: 4943318.
DOI: 10.2174/092986711797379267.
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.
Haan C, Behrmann I, Haan S
J Cell Mol Med. 2010; 14(3):504-27.
PMID: 20132407
PMC: 3823453.
DOI: 10.1111/j.1582-4934.2010.01018.x.
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells.
Schoof N, von Bonin F, Trumper L, Kube D
Cell Commun Signal. 2009; 7:17.
PMID: 19607667
PMC: 2714310.
DOI: 10.1186/1478-811X-7-17.
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S, Bacher U, Haferlach C, Geer T, Muller P, Mittermuller J
Haematologica. 2009; 94(3):414-8.
PMID: 19252176
PMC: 2649350.
DOI: 10.3324/haematol.13223.
